Latest Development Pipeline News

Brazilian Rare Earths Limited (BRE) reports a robust scoping study for its Amargosa Bauxite-Gallium Project, alongside a strategic heavy rare earths partnership and a strong cash position to accelerate development.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

St Barbara Limited reports strong feasibility outcomes for its New Simberi Gold Project and Nova Scotia developments, backed by significant strategic investments and regulatory approvals.

Aurum Resources has reported further high-grade gold intercepts at its BMT3 deposit within the Boundiali Gold Project, reinforcing resource confidence ahead of key 2026 milestones. The company is advancing aggressive drilling and development plans backed by a strong cash position.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Tesoro Gold Limited ended December 2025 with a strong cash position of AUD 29.2 million, supporting more than four quarters of exploration and operating activities. The company’s latest cash flow report reveals steady financing inflows amid ongoing investment in its gold exploration projects.

Cyprium Metals has raised A$41 million through an oversubscribed equity placement and entitlement offer to accelerate exploration and production growth at its flagship Nifty Copper Complex and regional projects.

Genesis Energy has reported a robust second-quarter performance for FY26, underpinned by strong hydro generation and record-low thermal output, prompting an upward revision of its full-year earnings guidance. The company’s strategic focus on portfolio flexibility and renewable projects continues to drive margin quality and operational progress.

Noxopharm has successfully completed the final multiple-dose cohort of its HERACLES trial for SOF-SKN™, reporting no significant safety concerns and paving the way for Phase II-enabling studies.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Clinuvel Pharmaceuticals has initiated dosing in a preclinical study of its novel controlled-release injectable peptide platform, VLRX-L, aiming to enhance drug delivery for melanocortin-based therapies. Preliminary results are expected in the second half of 2026.

Robex Resources shareholders have overwhelmingly approved a merger with Predictive Discovery, setting the stage for a leading gold producer in West Africa with combined annual output projected to exceed 400,000 ounces by 2029.